Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harrah Chiang

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Cureus|June 21, 2024
Report of Cholangiocarcinoma With Transheterozygous BRCA1 and BRCA2 Co-mutationNicholas Prabhakar, Harrah Chiang, Edward Nabrinsky, et al.
Cureus|June 10, 2024
T-Cell Lymphoproliferative Disorders Following Allogeneic Bone Marrow Transplant: A Report of Two Cases and a Literature ReviewNicholas Prabhakar, Harrah Chiang, Irma Munoz Verdugo, et al.
Cureus|April 22, 2021
Simulating Early Clinical Experiences With Surgical Procedures in the Anatomy LaboratoryTayler Gant, Harrah Chiang, Benjamin D Harman, et al.
Cancer Immunology, Immunotherapy : CII|November 11, 2017
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapyDavid Briere, Niranjan Sudhakar, David M Woods, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D Engstrom, Ruth Aranda, Matthew Lee, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Cureus|June 21, 2024
Report of Cholangiocarcinoma With Transheterozygous BRCA1 and BRCA2 Co-mutationNicholas Prabhakar, Harrah Chiang, Edward Nabrinsky, et al.
Cureus|June 10, 2024
T-Cell Lymphoproliferative Disorders Following Allogeneic Bone Marrow Transplant: A Report of Two Cases and a Literature ReviewNicholas Prabhakar, Harrah Chiang, Irma Munoz Verdugo, et al.
Cureus|April 22, 2021
Simulating Early Clinical Experiences With Surgical Procedures in the Anatomy LaboratoryTayler Gant, Harrah Chiang, Benjamin D Harman, et al.
Cancer Immunology, Immunotherapy : CII|November 11, 2017
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapyDavid Briere, Niranjan Sudhakar, David M Woods, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D Engstrom, Ruth Aranda, Matthew Lee, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
Pageof 1